CIDP (Chronic Inflammatory Demyelinating Polyneuropathy)

Affects approximately 1–9 per 100,000 people in the U.S.·7 treatments

CIDP is a rare neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. It occurs when the immune system attacks the myelin sheath protecting nerves, leading to numbness, tingling, and difficulty walking. Treatment typically involves IVIG, subcutaneous immunoglobulin, or corticosteroids.

You may qualify for clinical trials that provide Gamunex-C at no cost

Clinical trials may give you access to this treatment while helping advance medical research

Search Trials

Most insurers require confirmation of CIDP diagnosis through electrodiagnostic studies (nerve conduction velocity and EMG). Some plans require a trial of oral corticosteroids before approving IVIG. Dose and frequency of IVIG are closely monitored — insurers often require documentation of functional improvement to continue therapy beyond the initial authorization period.

IVIG dose exceeds payer-preferred frequency or quantity limits

Very Common

Diagnosis not confirmed by nerve conduction study or lumbar puncture

Common

Step therapy requires trial of corticosteroids before IVIG

Common

Insufficient documentation of functional impairment or disease progression

Occasional

Subcutaneous immunoglobulin (SCIg) required before IV formulation

Occasional

  1. 1.Include nerve conduction study results and EMG findings confirming demyelination
  2. 2.Document functional impairment using validated scales (INCAT, ONLS, or grip strength)
  3. 3.Show measurable improvement or stabilization with current IVIG therapy
  4. 4.If corticosteroids failed or are contraindicated, document specific reasons (e.g., diabetes, osteoporosis)
  5. 5.Request peer-to-peer with a neurologist reviewer — CIDP denials often involve non-specialist reviewers

Active clinical trials that may provide treatment at no cost.

Copay cards, patient assistance programs, and foundation grants for this condition's treatments.

Want to know what you'll actually pay?

Estimate your annual out-of-pocket cost with and without assistance programs.

Estimate My Costs

Denied for CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) Treatment?

Ellen can decode your denial, find your appeal strategy, and generate your appeal letter — free.